InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,311.48
(
0.67%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 111

Friday, 04/20/2018 9:07:51 AM

Friday, April 20, 2018 9:07:51 AM

Post# of 438
EBIO will read out Ph3 Bladder Cancer data in May-June/18.

Bladder cancer is a $1B pa commercial opty. A 20% market penetration could lead to a 1.2B MC

As of 3/18, Cash = $25mn with MC = ~$65mn

The initial commercial opty would be ~25K patients (who have failed standard of care and refuse cystecomy). The most recently approved therapy is priced at $37K.

Biotech stocks usually trade 5-10x revenues. At a multiple of 6, EBIO MC would be $1.2B

Watch AUA meeting in May/18
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up